ITMCTR2200005858招募中未知
A multicenter, double-blind, double-dummy, randomized controlled trial of the Chinese herbal medicine Linggui granule for patients with asthenospermia
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 22 至 40（—）
- 性别
- Male
入选标准
- •(1) Study participants must meet the diagnostic criteria of male infertility.
- •(2) Study participants must meet the diagnostic criteria of AZS.
- •(3) Men aged 22 to 45 years
- •(4) The participant must sign informed consent forms
排除标准
- •(1)with infertility caused by organic lesions of the reproductive system
- •(2)with infertility caused by the inability to complete sexual intercourse, including but not limited to erectile dysfunction, ejaculatory disorder
- •(3)with reproductive system infection, such as chlamydia trachomatis or mycoplasma infection
- •(4)with abnormal sex hormone
- •(5)with palpable varicocele
- •(6)with a history of allergy to any medicine or ingredients used in this study
- •(7)complicated with mental diseases, malignant tumors, or serious organic diseases
- •(8)use drugs affecting the experimental study within 3 months
研究者
相似试验
进行中（未招募）
1 期
A clinical study for testing the contraceptive efficacy, tolerability and safety of dienogest 2 mg / ethinyl estradiol 0.02 mg during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mgOral contraception for females aged 18-45MedDRA version: 20.0Level: SOCClassification code 10042613Term: Surgical and medical proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10030970Term: Oral contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-001877-97-HUChemo Research S.L.1,018
进行中（未招募）
1 期
A clinical study for testing the contraceptive efficacy, tolerability and safety of dienogest 2 mg / ethinyl estradiol 0.02 mg during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mgOral contraception for females aged 18-45MedDRA version: 20.0Level: SOCClassification code 10042613Term: Surgical and medical proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10030970Term: Oral contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-001877-97-PTChemo Research S.L.1,018
进行中（未招募）
1 期
A clinical study for testing the contraceptive efficacy, tolerability and safety of dienogest 2 mg / ethinyl estradiol 0.02 mg during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mgOral contraception for females aged 18-45MedDRA version: 20.0Level: SOCClassification code 10042613Term: Surgical and medical proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10030970Term: Oral contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-001877-97-ESChemo Research S.L.1,018
进行中（未招募）
1 期
A clinical study for testing the contraceptive efficacy, tolerability and safety of dienogest 2 mg / ethinyl estradiol 0.02 mg during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mgOral contraception for females aged 18-45MedDRA version: 20.0Level: SOCClassification code 10042613Term: Surgical and medical proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10030970Term: Oral contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-001877-97-CZChemo Research S.L.1,018
进行中（未招募）
1 期
A clinical study for testing the contraceptive efficacy, tolerability and safety of dienogest 2 mg / ethinyl estradiol 0.02 mg during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mgEUCTR2019-001877-97-SKChemo Research S.L.1,018